移动健康(mHealth)干预用于结核病患者戒烟:一项整群随机临床试验
该多中心整群随机临床试验于2023年9月18日至2025年1月2日在孟加拉国和巴基斯坦的27家结核病诊所开展,按2:1随机分配至mHealth组或常规护理组,纳入≥15岁、过去4周内诊断为药物敏感肺结核、每日吸烟且愿意戒烟并有手机的患者。mHealth组(n=720)在结核治疗期间接受短信(前2个月每日、后4个月每月),常规护理组(n=360)接受书面戒烟信息。主要终点为6个月时自报并经一氧化碳呼气试验生化验证的持续戒烟率:mHealth组41.7% vs 常规护理组15.3%(RR 3.0,95%CI 2.0-4.9)。mHealth组死亡率3.5% vs 常规护理组7.5%(HR 0.4,95%CI 0.2-0.9);治疗成功率和治疗依从性无显著差异。
要点
- 在药物敏感肺结核每日吸烟者中,mHealth短信干预6个月持续戒烟率41.7%(300/720)vs 常规护理15.3%(55/360),RR 3.0(95%CI 2.0-4.9)。
- mHealth组死亡率3.5% vs 常规护理组7.5%,HR 0.4(95%CI 0.2-0.9)。
- mHealth组与常规护理组平均结核治疗依从天数174.3天(SD 21.5)vs 178.0天(SD 12.1),P=0.23;治疗成功率89.3% vs 85.6%,RR 1.2(95%CI 0.9-1.6)。
- 治疗失败(0.1% vs 0.5%)和治疗脱失(中断结核治疗≥2个月,3.1% vs 1.9%)均不常见。
- mHealth短信方案为结核治疗期间前2个月每日发送、后4个月每月发送,鼓励戒烟。
适用人群与场景
- 纳入标准:年龄≥15岁,过去4周内诊断为药物敏感肺结核,每日吸烟,愿意戒烟,并能使用手机。
- 场景:孟加拉国和巴基斯坦的27家结核病诊所。
处置流程与药物剂量
- mHealth组(n=720)在结核治疗期间接受短信干预:前2个月每日发送,后4个月每月发送,内容为鼓励戒烟。
- 常规护理组(n=360)接受书面戒烟信息。
研究设计与关键结果
- 研究类型:多中心整群随机临床试验,27家结核病诊所按2:1随机分配至mHealth组或常规护理组,随访6个月。
- 样本量:评估9232例,随机化1080例(mHealth组720例,常规护理组360例),985例完成试验(91%);大多数为男性(mHealth组96.9%,常规护理组95.8%)。
- 主要终点:6个月自报并经生化验证的持续戒烟率mHealth组41.7%(300/720)vs 常规护理组15.3%(55/360),RR 3.0(95%CI 2.0-4.9)。
- 关键次要终点:平均结核治疗依从天数mHealth组174.3天(SD 21.5)vs 常规护理组178.0天(SD 12.1),P=0.23;治疗成功率89.3% vs 85.6%,RR 1.2(95%CI 0.9-1.6)。
- 其他次要终点:治疗失败率0.1% vs 0.5%,治疗脱失率3.1% vs 1.9%,均不常见;死亡率mHealth组3.5% vs 常规护理组7.5%,HR 0.4(95%CI 0.2-0.9)。
证据类型、等级与局限
- 证据类型:整群随机临床试验,注册号ISRCTN86971818。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为mHealth干预能有效帮助吸烟的结核病患者戒烟,并且是可行且有效的干预措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Smoking worsens outcomes in people with tuberculosis (TB), while quitting hastens recovery.
OBJECTIVE: To assess the effectiveness of a mobile health (mHealth) intervention for achieving self-reported continuous tobacco abstinence at 6 months, supported by biochemical verification at 6 months, compared with usual care in people with TB.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, cluster randomized clinical trial conducted between September 18, 2023, and January 2, 2025, randomizing (2:1) 27 TB clinics in Bangladesh and Pakistan to mHealth or usual care groups. The follow-up was 6 months. Participants were eligible if they were 15 years or older, had been diagnosed with drug-sensitive pulmonary TB in the past 4 weeks, smoked daily, were willing to quit, and had access to mobile phones.
INTERVENTION: The mHealth group (n = 720) received text messages throughout TB treatment, daily for 2 months then monthly for 4 months, encouraging tobacco cessation. The usual care group (n = 360) received written information on tobacco cessation.
MAIN OUTCOMES AND MEASURES: The primary outcome was self-reported continuous abstinence at 6 months, verified biochemically using carbon monoxide breath test at 6 months. Secondary outcomes included self-reported point abstinence at 9 weeks and 6 months, TB treatment adherence (days receiving TB treatment), TB treatment success (cured + completed treatment), TB treatment failure, TB treatment default (interruption of TB treatment for ≥2 months), and death.
RESULTS: Of 9232 patients assessed for eligibility, 1080 were randomized; most were male (mHealth, 96.9%; usual care, 95.8%), and 985 were retained throughout the trial (91%). For the primary outcome, 300 of 720 participants (41.7%) in the mHealth group demonstrated self-reported and biochemically verified continuous abstinence at 6 months, compared with 55 of 360 (15.3%) in the usual care group (risk ratio, 3.0 [95% CI, 2.0-4.9]). In the mHealth vs usual care groups, respectively, mean TB treatment adherence was 174.3 (SD, 21.5) days vs 178.0 (SD, 12.1) days (P = .23), and treatment success was 89.3% vs 85.6% (risk ratio, 1.2 [95% CI, 0.9-1.6]). TB treatment failure (0.1% vs 0.5%) and default (3.1% vs 1.9%) were uncommon. Mortality was lower with mHealth (3.5%) vs usual care (7.5%) (hazard ratio, 0.4 [95%CI, 0.2-0.9]).
CONCLUSIONS AND RELEVANCE: An mHealth intervention was effective in achieving continuous abstinence in people with TB who smoked. mHealth is a feasible and effective intervention to help patients with TB quit smoking.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN86971818.
参考来源
- Zahid M, Rahman F, Danaee M, et al. An mHealth (Mobile Health) Intervention for Smoking Cessation in People With Tuberculosis: A Cluster Randomized Clinical Trial. JAMA. 2026. PMID: 41428342. doi:10.1001/jama.2025.20765
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。